De novo microdeletions and point mutations affecting SOX2 in three individuals with intellectual disability but without major eye malformations
Loss‐of‐function mutations and deletions of the SOX2 gene are known to cause uni‐ and bilateral anophthalmia and microphthalmia as well as related disorders such as anophthalmia‐esophageal‐genital syndrome. Thus, anophthalmia/microphthalmia is the primary indication for targeted, “phenotype first” a...
Gespeichert in:
Veröffentlicht in: | American journal of medical genetics. Part A 2017-02, Vol.173 (2), p.435-443 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Loss‐of‐function mutations and deletions of the SOX2 gene are known to cause uni‐ and bilateral anophthalmia and microphthalmia as well as related disorders such as anophthalmia‐esophageal‐genital syndrome. Thus, anophthalmia/microphthalmia is the primary indication for targeted, “phenotype first” analyses of SOX2. However, SOX2 mutations are also associated with a wide range of non‐ocular abnormalities, such as postnatal growth retardation, structural brain anomalies, hypogenitalism, and developmental delay. The present report describes three patients without anophthalmia/microphthalmia and loss‐of‐function mutations or microdeletions of SOX2 who had been investigated in a “genotype first” manner due to intellectual disability/developmental delay using whole exome sequencing or chromosomal microarray analyses. This result prompted us to perform SOX2 Sanger sequencing in 192 developmental delay/intellectual disability patients without anophthalmia or microphthalmia. No additional SOX2 loss‐of‐function mutations were detected in this cohort, showing that SOX2 is clearly not a major cause of intellectual disability without anophthalmia/microphthalmia. In our three patients and four further, reported “genotype first” SOX2 microdeletion patients, anophthalmia/microphthalmia was present in less than half of the patients. Thus, SOX2 is another example of a gene whose clinical spectrum is broadened by the generation of “genotype first” findings using hypothesis‐free, genome‐wide methods. © 2016 Wiley Periodicals, Inc. |
---|---|
ISSN: | 1552-4825 1552-4833 |
DOI: | 10.1002/ajmg.a.38034 |